AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7219899 — intervention group
Group type: COMPARATOR
Intervention: Control (diet and physical activity without specified intensity)
Number of subjects: 0
Study 7219899 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence of myocardial infarction
Number of subjects: 0
Study 30378087 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium tosylate (GT) 3.75% applied once daily for 4 weeks
Number of subjects: 463
Study 30378087 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied once daily for 4 weeks
Number of subjects: 463
Study 30378087 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium tosylate (GT)
Number of subjects: 463
Study 30378087 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 463
Study 28641840 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month DAPT
Number of subjects: 2021
Study 28641840 — intervention group
Group type: COMPARATOR
Intervention: 24-month DAPT
Number of subjects: 2021
Study 25642584 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 0
Study 25642584 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational MI without directive elements (spirit‐only MI)
Number of subjects: 0
Study 23301674 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive eye assessment including visual acuity, orthoptic assessment, cycloplegic autorefraction, ocular biometric variables, and ophthalmic photographs.
Number of subjects: 1344
Study 21645997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy (CET)
Number of subjects: 50
Study 21645997 — intervention group
Group type: COMPARATOR
Intervention: Enriched Supportive Therapy (Control)
Number of subjects: 50
Study 18423807 — intervention group
Group type: EXPERIMENTAL
Intervention: FX‐E membrane (super-flux)
Number of subjects: 30
Study 18423807 — intervention group
Group type: COMPARATOR
Intervention: FX‐60 membrane (high-flux)
Number of subjects: 30
Study 16503669 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC2 at 100% intensity (n = 12)
Number of subjects: 51
Study 16503669 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC2 at 90% intensity (n = 13)
Number of subjects: 51
Study 16503669 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC2 at 80% intensity (n = 14)
Number of subjects: 51
Study 16503669 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 51
Study 12766639 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure at the relaxation point
Number of subjects: 36
Study 12766639 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 36
Study 10679908 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) alpha and beta (>10 U/mL), long-term exposure (144 hr)
Number of subjects: 50
Study 10679908 — intervention group
Group type: COMPARATOR
Intervention: Head and neck squamous cell carcinomas (HNSCC)
Number of subjects: 50
Study 9358076 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO (600 U/kg, iv, 6 times over 3 weeks)
Number of subjects: 10
Study 9358076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9358076 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 10
Study 1606113 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring at home
Number of subjects: 99
Study 1606113 — intervention group
Group type: COMPARATOR
Intervention: Monitoring in hospital
Number of subjects: 99
Study 2863380 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 0
Study 2863380 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic group (maintenance antipsychotic medication)
Number of subjects: 0
Study 2863380 — intervention group
Group type: COMPARATOR
Intervention: Control group (drug-free)
Number of subjects: 0
Study 29581985 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing group (n = 50)
Number of subjects: 100
Study 27259552 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily antibiotic prophylaxis for 12 months
Number of subjects: 0
Study 27259552 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 0
Study 24261328 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate-enriched bicarbonate based dialysate (CD) with 30% reduced heparin dose
Number of subjects: 30
Study 24261328 — intervention group
Group type: COMPARATOR
Intervention: Acetate-enriched bicarbonate based dialysate with standard heparin dose of ∼ 100 IU/kg (Treatment A)
Number of subjects: 30
Study 22889151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) with chemotherapy for 6 months, followed by 3 months follow-up
Number of subjects: 39
Study 22889151 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without UDCA for 9 months
Number of subjects: 39
Study 20549040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 4 mg triamcinolone acetonide
Number of subjects: 14
Study 20549040 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 eyes without diabetic macular edema)
Number of subjects: 14
Study 18826853 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 32
Study 18826853 — intervention group
Group type: COMPARATOR
Intervention: Standard phosphate-binder therapy (Stx)
Number of subjects: 32
Study 15796145 — intervention group
Group type: EXPERIMENTAL
Intervention: Protenplus (oral protein-energy supplement)
Number of subjects: 65
Study 15796145 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 65
Study 12783045 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise
Number of subjects: 8
Study 12783045 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 8
Study 10542989 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with heat killed Mycobacterium vaccae
Number of subjects: 40
Study 10542989 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 40
Study 8904433 — intervention group
Group type: EXPERIMENTAL
Intervention: famciclovir
Number of subjects: 40
Study 8904433 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 1906987 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN for 7 to 15 days before surgery and 3 days afterward
Number of subjects: 395
Study 1906987 — intervention group
Group type: COMPARATOR
Intervention: No perioperative TPN (control group)
Number of subjects: 395
Study 6358477 — intervention group
Group type: EXPERIMENTAL
Intervention: seminar and relaxation training
Number of subjects: 71
Study 6358477 — intervention group
Group type: COMPARATOR
Intervention: seminar and a placebo condition
Number of subjects: 71
Study 6358477 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 71
Study 28009600 — intervention group
Group type: EXPERIMENTAL
Intervention: High dollar payout category physicians with one malpractice claim payout
Number of subjects: 0
Study 28009600 — intervention group
Group type: COMPARATOR
Intervention: All physicians with a single payout
Number of subjects: 0
Study 28009600 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dollar payouts per physician
Number of subjects: 0
Study 30723744 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling surgery alone (S group, n=36)
Number of subjects: 76
Study 30723744 — intervention group
Group type: COMPARATOR
Intervention: Concomitant sling and transvaginal mesh surgery (M group, n=40)
Number of subjects: 76
Study 28687232 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (750 mg IV every 4 weeks for 6 doses)
Number of subjects: 105
Study 28687232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 28687232 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 105
Study 27468589 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory screw
Number of subjects: 32
Study 27468589 — intervention group
Group type: COMPARATOR
Intervention: Hyrax screw
Number of subjects: 32
Study 24462856 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia module (MM)
Number of subjects: 41
Study 24462856 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 21602539 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 143
Study 21602539 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 143
Study 21602539 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care
Number of subjects: 143
Study 19244174 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg injection every 4 weeks for 2 years)
Number of subjects: 2706
Study 19244174 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20 or 40 mg daily for 2 years)
Number of subjects: 2706
Study 17313322 — intervention group
Group type: EXPERIMENTAL
Intervention: O(2) supplementation
Number of subjects: 38
Study 17313322 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 38
Study 17313322 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 38
Study 16320180 — intervention group
Group type: EXPERIMENTAL
Intervention: Maitland's manual mobilization, treated two times a week for three weeks
Number of subjects: 36
Study 16320180 — intervention group
Group type: COMPARATOR
Intervention: Control group, received no treatment
Number of subjects: 36
Study 12215276 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran uterine artery embolization
Number of subjects: 38
Study 9676352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release theophylline (500 mg) with standard breakfast
Number of subjects: 12
Study 9676352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release theophylline (500 mg) with cholecystokinin (0.3 microgram/kg)
Number of subjects: 12
Study 9676352 — intervention group
Group type: COMPARATOR
Intervention: Sustained release theophylline (500 mg) under fasting conditions
Number of subjects: 12
Study 8045953 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CRH (100 micrograms ovine) and lysine vasopressin (1 IU over 15 min)
Number of subjects: 10
Study 8045953 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CRH and lysine vasopressin
Number of subjects: 10
Study 3054451 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX, 1,000 mg/m2)
Number of subjects: 330
Study 3054451 — intervention group
Group type: COMPARATOR
Intervention: Cranial irradiation/sequential chemotherapy (RTSC)
Number of subjects: 330
Study 3054451 — intervention group
Group type: COMPARATOR
Intervention: Historical institutional control regimens
Number of subjects: 330
Study 3054451 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HDMTX and RTSC)
Number of subjects: 330
Study 29856526 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine small intestine submucosal graft (SIS)
Number of subjects: 47
Study 29856526 — intervention group
Group type: COMPARATOR
Intervention: Control (no graft)
Number of subjects: 47
Study 27928874 — intervention group
Group type: EXPERIMENTAL
Intervention: Payment for performance (P4P)
Number of subjects: 150
Study 26026801 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention from a multidisciplinary team
Number of subjects: 42
Study 26026801 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study 23894039 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year trastuzumab treatment
Number of subjects: 425
Study 23894039 — intervention group
Group type: COMPARATOR
Intervention: Observation arm (no trastuzumab)
Number of subjects: 425
Study 21679432 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-centred, multi-component intervention (balanced information, group discussion, coaching exercise) + MMR information leaflet
Number of subjects: 142
Study 21679432 — intervention group
Group type: COMPARATOR
Intervention: Leaflet only (Control)
Number of subjects: 142
Study 21679432 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (Intervention and Control)
Number of subjects: 142
Study 21679432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 142
Study 19080095 — intervention group
Group type: EXPERIMENTAL
Intervention: AHH group (acute hypervolemic hemodilution)
Number of subjects: 36
Study 19080095 — intervention group
Group type: COMPARATOR
Intervention: CNT group (control)
Number of subjects: 36
Study 19080095 — intervention group
Group type: EXPERIMENTAL
Intervention: AHH group
Number of subjects: 36
Study 16825698 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and infant vitamin A supplementation (400,000 IU for mothers, 50,000 IU for infants)
Number of subjects: 1592
Study 16825698 — intervention group
Group type: COMPARATOR
Intervention: Mothers received vitamin A and infants received placebo
Number of subjects: 1592
Study 16825698 — intervention group
Group type: COMPARATOR
Intervention: Mothers received placebo and infants received vitamin A
Number of subjects: 1592
Study 16825698 — intervention group
Group type: COMPARATOR
Intervention: Mothers and infants received placebo
Number of subjects: 1592
Study 16825698 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant HIV infection
Number of subjects: 1592
Study 16825698 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex and lower total body iron at birth
Number of subjects: 1592
Study 16825698 — intervention group
Group type: EXPERIMENTAL
Intervention: Early infection, low maternal CD4+ lymphocyte count at recruitment, and frequent morbidity in HIV-positive infants
Number of subjects: 1592
Study 16825698 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month plasma ferritin concentrations <12 microg/L in HIV-negative infants
Number of subjects: 1592
Study 16825698 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal HIV infection
Number of subjects: 1592
Study 12646297 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls with earlier onset depression
Number of subjects: 87
Study 12646297 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys with later onset depression
Number of subjects: 87
Study 12646297 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 87
Study 12646297 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 87
Study 12646297 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid disorders
Number of subjects: 87
Study 12646297 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at depression onset
Number of subjects: 87
Study 12646297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex differences
Number of subjects: 87
Study 11386628 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice assessment process
Number of subjects: 136
Study 11386628 — intervention group
Group type: COMPARATOR
Intervention: Fill-in-the-blank assessment process
Number of subjects: 136
Study 9744143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine coat-core (CC) 20-40 mg once daily
Number of subjects: 229
Study 9744143 — intervention group
Group type: COMPARATOR
Intervention: Felodipine 5-10 mg once daily
Number of subjects: 229
Study 8038542 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Triggered Ventilation (PTV)
Number of subjects: 40
Study 8038542 — intervention group
Group type: COMPARATOR
Intervention: Synchronous Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 40
Study 3176835 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid (spinal) bupivacaine 0.5%
Number of subjects: 40
Study 3176835 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine 0.5%
Number of subjects: 40
Study 31130005 — intervention group
Group type: EXPERIMENTAL
Intervention: Group prenatal care with a behavioral sleep intervention (adapted from CBT-I online program Go! to Sleep®)
Number of subjects: 53
Study 31130005 — intervention group
Group type: COMPARATOR
Intervention: Group prenatal care (control)
Number of subjects: 53
Study 30825342 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training (CT) intervention (resistance plus endurance training) for 20 weeks
Number of subjects: 28
Study 30825342 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercise)
Number of subjects: 28
Study 27955850 — intervention group
Group type: EXPERIMENTAL
Intervention: YES IN (Oral immunonutrition) administered for 8 days (3 sachets a day)
Number of subjects: 84
Study 27955850 — intervention group
Group type: COMPARATOR
Intervention: NOT IN (no immunonutrition)
Number of subjects: 84
Study 27955850 — intervention group
Group type: COMPARATOR
Intervention: NOT IN (no immunonutrition) in patients with rectal cancer
Number of subjects: 84
Study 27955850 — intervention group
Group type: EXPERIMENTAL
Intervention: YES IN (Oral immunonutrition)
Number of subjects: 84
Study 25349058 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic diet (PD)
Number of subjects: 49
Study 25349058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic nutrition recommendations (NNR)
Number of subjects: 49
Study 24148035 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First intervention
Number of subjects: 497
Study 24148035 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (no housing or support)
Number of subjects: 497
Study 20924595 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 150 mg
Number of subjects: 6
Study 20924595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 19781408 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib, 100 mg
Number of subjects: 1623
Study 19781408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1623
Study 16423675 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral annulus motion (MAM)
Number of subjects: 408
Study 15608806 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (exact details not specified)
Number of subjects: 250
Study 15608806 — intervention group
Group type: COMPARATOR
Intervention: Comparison with New Zealand population norms
Number of subjects: 250
Study 15608806 — intervention group
Group type: EXPERIMENTAL
Intervention: Modest weight loss intervention (exact details not specified)
Number of subjects: 250
Study 11764221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge insole with elastic strapping of the subtalar joint (n = 46)
Number of subjects: 90
Study 11764221 — intervention group
Group type: COMPARATOR
Intervention: Traditional shoe insert wedge insole (n = 44)
Number of subjects: 90
Study 9256553 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation-based HIV risk reduction intervention
Number of subjects: 102
Study 9256553 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 102
Study 8440102 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 10 cm H2O
Number of subjects: 27
Study 8440102 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 15 cm H2O
Number of subjects: 27
Study 8440102 — intervention group
Group type: COMPARATOR
Intervention: PEEP 5 cm H2O
Number of subjects: 27
Study 8440102 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 20 cm H2O
Number of subjects: 27
Study 31866170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (educational sessions and decision aid materials)
Number of subjects: 7635
Study 31866170 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care without intervention)
Number of subjects: 7635
Study 31866170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 7635
Study 31866170 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 7635
Study 31306056 — intervention group
Group type: EXPERIMENTAL
Intervention: %PC 38:3 concentration
Number of subjects: 839
Study 31306056 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 839
Study 28916311 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (5 mg daily, escalated to 15 mg if tolerated)
Number of subjects: 89
Study 28916311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 28916311 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 89
Study 24938453 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% trichloroacetic acid
Number of subjects: 0
Study 24938453 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% trichloroacetic acid
Number of subjects: 0
Study 24938453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0
Study 23299649 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of upper first molars and lightwire multibracket (MB) appliance
Number of subjects: 154
Study 23299649 — intervention group
Group type: COMPARATOR
Intervention: Herbst-MB appliance
Number of subjects: 154
Study 21447661 — intervention group
Group type: EXPERIMENTAL
Intervention: PRANDIAL strategy (n = 557)
Number of subjects: 1115
Study 21447661 — intervention group
Group type: COMPARATOR
Intervention: BASAL strategy (n = 558)
Number of subjects: 1115
Study 18375649 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 17075913 — intervention group
Group type: EXPERIMENTAL
Intervention: Early interventions following trauma (initiated within the first 3 months after exposure)
Number of subjects: 0
Study 12859326 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors (PIs) in the salvage regimen
Number of subjects: 159
Study 12859326 — intervention group
Group type: EXPERIMENTAL
Intervention: >8 months on treatment
Number of subjects: 159
Study 12859326 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute decrease in plasma viral load (pVL)
Number of subjects: 159
Study 12859326 — intervention group
Group type: EXPERIMENTAL
Intervention: Virological responders (> or =1 log10 HIV-1 RNA copies/mL decrease)
Number of subjects: 159
Study 12859326 — intervention group
Group type: EXPERIMENTAL
Intervention: Virologically non-responders
Number of subjects: 159
Study 11339007 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Doppler ultrasonography (PD)
Number of subjects: 46
Study 11339007 — intervention group
Group type: COMPARATOR
Intervention: Lugol's iodine treatment
Number of subjects: 46
Study 8970407 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol OROS 190 mg once daily
Number of subjects: 65
Study 8970407 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol OROS 285 mg once daily
Number of subjects: 65
Study 8970407 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 100 mg 2 or 3 times daily
Number of subjects: 65